The global Preclinical Assets market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Preclinical Assets market research.
Key companies engaged in the Preclinical Assets industry include Eurofins Scientific, Viroclinics Xplore, SGS, Intertek Group, AmplifyBio, IQVIA, ICON plc, Medpace and Pharmatest Services, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Preclinical Assets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Preclinical Assets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Preclinical Assets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Eurofins Scientific
Viroclinics Xplore
SGS
Intertek Group
AmplifyBio
IQVIA
ICON plc
Medpace
Pharmatest Services
PPD
Crown Bioscience
Comparative Biosciences
TCG Lifesciences
Domainex
Absorption Systems
Segment by Type
Bioanalysis and DMPK Studies
Toxicology Testing
Compound Management
Safety Pharmacology
Others
Segment by Application
Biopharmaceutical Companies
Government Institutes
Research institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Preclinical Assets report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Preclinical Assets Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Bioanalysis and DMPK Studies
1.2.3 Toxicology Testing
1.2.4 Compound Management
1.2.5 Safety Pharmacology
1.2.6 Others
1.3 Market by Application
1.3.1 Global Preclinical Assets Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Biopharmaceutical Companies
1.3.3 Government Institutes
1.3.4 Research institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Preclinical Assets Market Perspective (2018-2029)
2.2 Preclinical Assets Growth Trends by Region
2.2.1 Global Preclinical Assets Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Preclinical Assets Historic Market Size by Region (2018-2023)
2.2.3 Preclinical Assets Forecasted Market Size by Region (2024-2029)
2.3 Preclinical Assets Market Dynamics
2.3.1 Preclinical Assets Industry Trends
2.3.2 Preclinical Assets Market Drivers
2.3.3 Preclinical Assets Market Challenges
2.3.4 Preclinical Assets Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Preclinical Assets Players by Revenue
3.1.1 Global Top Preclinical Assets Players by Revenue (2018-2023)
3.1.2 Global Preclinical Assets Revenue Market Share by Players (2018-2023)
3.2 Global Preclinical Assets Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Preclinical Assets Revenue
3.4 Global Preclinical Assets Market Concentration Ratio
3.4.1 Global Preclinical Assets Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Preclinical Assets Revenue in 2022
3.5 Preclinical Assets Key Players Head office and Area Served
3.6 Key Players Preclinical Assets Product Solution and Service
3.7 Date of Enter into Preclinical Assets Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Preclinical Assets Breakdown Data by Type
4.1 Global Preclinical Assets Historic Market Size by Type (2018-2023)
4.2 Global Preclinical Assets Forecasted Market Size by Type (2024-2029)
5 Preclinical Assets Breakdown Data by Application
5.1 Global Preclinical Assets Historic Market Size by Application (2018-2023)
5.2 Global Preclinical Assets Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Preclinical Assets Market Size (2018-2029)
6.2 North America Preclinical Assets Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Preclinical Assets Market Size by Country (2018-2023)
6.4 North America Preclinical Assets Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Preclinical Assets Market Size (2018-2029)
7.2 Europe Preclinical Assets Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Preclinical Assets Market Size by Country (2018-2023)
7.4 Europe Preclinical Assets Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Preclinical Assets Market Size (2018-2029)
8.2 Asia-Pacific Preclinical Assets Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Preclinical Assets Market Size by Region (2018-2023)
8.4 Asia-Pacific Preclinical Assets Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Preclinical Assets Market Size (2018-2029)
9.2 Latin America Preclinical Assets Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Preclinical Assets Market Size by Country (2018-2023)
9.4 Latin America Preclinical Assets Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Preclinical Assets Market Size (2018-2029)
10.2 Middle East & Africa Preclinical Assets Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Preclinical Assets Market Size by Country (2018-2023)
10.4 Middle East & Africa Preclinical Assets Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eurofins Scientific
11.1.1 Eurofins Scientific Company Detail
11.1.2 Eurofins Scientific Business Overview
11.1.3 Eurofins Scientific Preclinical Assets Introduction
11.1.4 Eurofins Scientific Revenue in Preclinical Assets Business (2018-2023)
11.1.5 Eurofins Scientific Recent Development
11.2 Viroclinics Xplore
11.2.1 Viroclinics Xplore Company Detail
11.2.2 Viroclinics Xplore Business Overview
11.2.3 Viroclinics Xplore Preclinical Assets Introduction
11.2.4 Viroclinics Xplore Revenue in Preclinical Assets Business (2018-2023)
11.2.5 Viroclinics Xplore Recent Development
11.3 SGS
11.3.1 SGS Company Detail
11.3.2 SGS Business Overview
11.3.3 SGS Preclinical Assets Introduction
11.3.4 SGS Revenue in Preclinical Assets Business (2018-2023)
11.3.5 SGS Recent Development
11.4 Intertek Group
11.4.1 Intertek Group Company Detail
11.4.2 Intertek Group Business Overview
11.4.3 Intertek Group Preclinical Assets Introduction
11.4.4 Intertek Group Revenue in Preclinical Assets Business (2018-2023)
11.4.5 Intertek Group Recent Development
11.5 AmplifyBio
11.5.1 AmplifyBio Company Detail
11.5.2 AmplifyBio Business Overview
11.5.3 AmplifyBio Preclinical Assets Introduction
11.5.4 AmplifyBio Revenue in Preclinical Assets Business (2018-2023)
11.5.5 AmplifyBio Recent Development
11.6 IQVIA
11.6.1 IQVIA Company Detail
11.6.2 IQVIA Business Overview
11.6.3 IQVIA Preclinical Assets Introduction
11.6.4 IQVIA Revenue in Preclinical Assets Business (2018-2023)
11.6.5 IQVIA Recent Development
11.7 ICON plc
11.7.1 ICON plc Company Detail
11.7.2 ICON plc Business Overview
11.7.3 ICON plc Preclinical Assets Introduction
11.7.4 ICON plc Revenue in Preclinical Assets Business (2018-2023)
11.7.5 ICON plc Recent Development
11.8 Medpace
11.8.1 Medpace Company Detail
11.8.2 Medpace Business Overview
11.8.3 Medpace Preclinical Assets Introduction
11.8.4 Medpace Revenue in Preclinical Assets Business (2018-2023)
11.8.5 Medpace Recent Development
11.9 Pharmatest Services
11.9.1 Pharmatest Services Company Detail
11.9.2 Pharmatest Services Business Overview
11.9.3 Pharmatest Services Preclinical Assets Introduction
11.9.4 Pharmatest Services Revenue in Preclinical Assets Business (2018-2023)
11.9.5 Pharmatest Services Recent Development
11.10 PPD
11.10.1 PPD Company Detail
11.10.2 PPD Business Overview
11.10.3 PPD Preclinical Assets Introduction
11.10.4 PPD Revenue in Preclinical Assets Business (2018-2023)
11.10.5 PPD Recent Development
11.11 Crown Bioscience
11.11.1 Crown Bioscience Company Detail
11.11.2 Crown Bioscience Business Overview
11.11.3 Crown Bioscience Preclinical Assets Introduction
11.11.4 Crown Bioscience Revenue in Preclinical Assets Business (2018-2023)
11.11.5 Crown Bioscience Recent Development
11.12 Comparative Biosciences
11.12.1 Comparative Biosciences Company Detail
11.12.2 Comparative Biosciences Business Overview
11.12.3 Comparative Biosciences Preclinical Assets Introduction
11.12.4 Comparative Biosciences Revenue in Preclinical Assets Business (2018-2023)
11.12.5 Comparative Biosciences Recent Development
11.13 TCG Lifesciences
11.13.1 TCG Lifesciences Company Detail
11.13.2 TCG Lifesciences Business Overview
11.13.3 TCG Lifesciences Preclinical Assets Introduction
11.13.4 TCG Lifesciences Revenue in Preclinical Assets Business (2018-2023)
11.13.5 TCG Lifesciences Recent Development
11.14 Domainex
11.14.1 Domainex Company Detail
11.14.2 Domainex Business Overview
11.14.3 Domainex Preclinical Assets Introduction
11.14.4 Domainex Revenue in Preclinical Assets Business (2018-2023)
11.14.5 Domainex Recent Development
11.15 Absorption Systems
11.15.1 Absorption Systems Company Detail
11.15.2 Absorption Systems Business Overview
11.15.3 Absorption Systems Preclinical Assets Introduction
11.15.4 Absorption Systems Revenue in Preclinical Assets Business (2018-2023)
11.15.5 Absorption Systems Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Eurofins Scientific
Viroclinics Xplore
SGS
Intertek Group
AmplifyBio
IQVIA
ICON plc
Medpace
Pharmatest Services
PPD
Crown Bioscience
Comparative Biosciences
TCG Lifesciences
Domainex
Absorption Systems
*If Applicable.